The estimated Net Worth of Mark Avagliano is at least $7.28 Миллион dollars as of 5 July 2024. Mr. Avagliano owns over 2,638 units of G1 Therapeutics Inc stock worth over $1,725,781 and over the last 5 years he sold GTHX stock worth over $73,606. In addition, he makes $5,478,390 as Chief Business Officer at G1 Therapeutics Inc.
Sign up
Mr. Avagliano GTHX stock SEC Form 4 insiders trading
Mark has made over 4 trades of the G1 Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 2,638 units of GTHX stock worth $6,621 on 5 July 2024.
The largest trade he's ever made was selling 8,151 units of G1 Therapeutics Inc stock on 13 May 2024 worth over $39,043. On average, Mark trades about 1,483 units every 83 days since 2019. As of 5 July 2024 he still owns at least 242,045 units of G1 Therapeutics Inc stock.
You can see the complete history of Mr. Avagliano stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mark Avagliano biography
Mark Avagliano serves as Chief Business Officer of the Company. Prior to joining us, he served as Vice President, Corporate Development at Pfizer Inc., from March 2004 to July 2019, where he was responsible for the evaluation, planning and execution of significant corporate level transactions and oversaw the Mergers and Acquisitions, Transactions & Valuations, and Out-licensing groups. At Pfizer, Mr. Avagliano successfully led the execution of numerous significant transactions, including acquisitions, divestitures, joint ventures, co-developments, co-promotions, product licenses, research collaborations, and public market separations. Prior to joining Pfizer in 2004, Mr. Avagliano held commercial and operational roles at Aventis Pharmaceuticals.
What is the salary of Mark Avagliano?
As the Chief Business Officer of G1 Therapeutics Inc, the total compensation of Mark Avagliano at G1 Therapeutics Inc is $5,478,390. There are no executives at G1 Therapeutics Inc getting paid more.
How old is Mark Avagliano?
Mark Avagliano is 44, he's been the Chief Business Officer of G1 Therapeutics Inc since 2019. There are 25 older and no younger executives at G1 Therapeutics Inc. The oldest executive at G1 Therapeutics Inc is Fredric Eshelman, 72, who is the Independent Director.
What's Mark Avagliano's mailing address?
Mark's mailing address filed with the SEC is 700 PARK OFFICES DRIVE, SUITE 200, , RESEARCH TRIANGLE PARK, NC, 27709.
Insiders trading at G1 Therapeutics Inc
Over the last 8 years, insiders at G1 Therapeutics Inc have traded over $53,962,020 worth of G1 Therapeutics Inc stock and bought 1,541,753 units worth $24,259,954 . The most active insiders traders include Capital Management, L.P.Ra ..., Fredric N Eshelman и Glenn P Muir. On average, G1 Therapeutics Inc executives and independent directors trade stock every 17 days with the average trade being worth of $198,620. The most recent stock trade was executed by Andrew Perry on 5 July 2024, trading 1,337 units of GTHX stock currently worth $3,356.
What does G1 Therapeutics Inc do?
g1 therapeutics is a clinical-stage company developing small-molecule therapies to address significant unmet needs in oncology. the company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of best-in-class compounds and first-in-class drug candidates.
What does G1 Therapeutics Inc's logo look like?
Complete history of Mr. Avagliano stock trades at G1 Therapeutics Inc
G1 Therapeutics Inc executives and stock owners
G1 Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Mark Avagliano,
Chief Business Officer -
James Hanson,
General Counsel, Secretary -
Mark Velleca,
President, Chief Executive Officer, Director -
Terry Murdock,
Chief Operating Officer -
Garry Nicholson,
Independent Chairman of the Board -
Jennifer Moses,
Chief Financial Officer -
Rajesh Malik,
Chief Medical Officer, Senior Vice President - Research and Development -
Dr. Mark A. Velleca M.D., Ph.D.,
Sr. Advisor & Director -
Mark Avagliano,
Chief Bus. Officer -
Dr. Rajesh K. Malik Ch.B., M.B., M.D.,
Chief Medical Officer and Sr. VP of R&D -
Dr. Rajesh K. Malik,
Chief Medical Officer and Sr. VP of R&D -
Andrew Perry,
Chief Commercial Officer -
Jennifer K. Moses CPA,
Chief Financial Officer -
Jennifer K. Moses,
Chief Financial Officer -
Seth Rudnick,
Independent Director -
Glenn Muir,
Independent Director -
Cynthia Schwalm,
Independent Director -
Fredric Eshelman,
Independent Director -
Willie Deese,
Independent Director -
Andrew Witty,
Independent Director -
John Bailey,
Independent Director -
Soma Gupta,
Chief Commercial Officer -
Jay Strum,
Chief Scientific Officer -
Terry L. Murdock,
Chief Operating Officer -
Blake Jensen,
VP of Quality & Compliance -
William C. Roberts,
VP of Investor Relations & Corp. Communications -
Dr. Jay C. Strum,
Chief Scientific Officer -
Alexander D. Smith M.S.,
VP of Technical Operations -
John E. Bailey Jr.,
CEO, Pres & Director -
Clay Hatteras Venture Advis...,
-
Capital Management, L.P.Ra ...,
-
Christy L Shaffer,
Director -
Ventures, Inc. Med Immune,
10% owner -
Ventures, Llc Eshelman,
10% owner -
Clay Hatteras Venture Advis...,
-
Barclay A Phillips,
SVP & Chief Financial Officer -
Monica R. Thomas,
Chief Legal & People Officer -
Jacks Lee,
-
John Demaree,
Chief Commercial Officer -
Alicia Secor,
-
Cynthia Louise Flowers,
-
Andrew Perry,
Chief Commercial Officer -
Norman Sharpless,
-
John W. V Umstead,
Chief Financial Officer